4.4 Review

Fecal Microbiota Transplantation for Chronic Liver Diseases: Current Understanding and Future Direction

Journal

DIGESTIVE DISEASES AND SCIENCES
Volume 65, Issue 3, Pages 897-905

Publisher

SPRINGER
DOI: 10.1007/s10620-020-06100-0

Keywords

Fecal microbiota transplantation (FMT); Chronic liver diseases; Alcoholic liver disease (ALD); Nonalcoholic liver disease (NAFLD); Nonalcoholic hepatitis (NASH); Bile acids

Funding

  1. Stanford ChEM-H physician-scientist research fellowship

Ask authors/readers for more resources

Chronic liver disease is a major cause of morbidity and mortality worldwide. Even though effective treatments are now available for most chronic viral hepatitis, treatment options for other causes of chronic liver disease remain inadequate. Recent research has revealed a previously unappreciated role that the human intestinal microbiome plays in mediating the development and progression of chronic liver diseases. The recent remarkable success of fecal microbiota transplantation (FMT) in treating Clostridioides difficile demonstrates that the intestinal microbiota can be manipulated to obtain favorable therapeutic benefits and that FMT may become an important component of a total therapeutic approach to effectively treat hepatic disorders.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available